{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:41Z","timestamp":1767134681728,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006624","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":143,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006624.pub2","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T14:47:59Z","timestamp":1263826079000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Amisulpride versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychosomatische und Medizin und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie der Universit\u00e4t Leipzig; Semmelweisstr. 10 04103 Leipzig Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim I","family":"Silveira da Mota Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Pelotas; Evidence Based Medicine Centre; Avenida Duque de Caxias, 250 Pelotas Brazil 96100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"Suppl 3","key":"10.1002\/14651858.CD006624.pub2-BIB0001|cit1","first-page":"S473","article-title":"Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study","volume":"15","author":"Bai","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0002|cit2","first-page":"30","article-title":"Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan","volume":"102","author":"Hwang","year":"2003","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006624.pub2-BIB0004|cit4","first-page":"S511","article-title":"A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia","volume":"15","author":"M\u00f6ller","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0006|cit5","unstructured":"Mortimer A The European First Episode Schizophrenia Trial: comparison of outcome in first episode schizophrenia with different low dose antipsychotic regimens (EUFEST) National Research Register 2003"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0005|cit6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","article-title":"A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia","volume":"19","author":"Mortimer","year":"2004","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0007|cit7","unstructured":"Singh V A six month international controlled trial of the therapeutic activity of amisulpride 200 to 800 mg\/day verses olanzapine 5 to 20 mg\/day in patients with schizophrenic disorders National Research Register 2001"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Olie","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006624.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S0924-977X(02)80466-7","article-title":"Ziprasidone vs amisulpride for negative symptoms of schizophrenia","volume":"12","author":"Olie","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerations of schizophrenia","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0011|cit11","first-page":"79","article-title":"Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia","volume":"6","author":"Nicholls","year":"2003","journal-title":"Journal of Drug Assessment"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0893-133X(02)00375-5","article-title":"Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study","volume":"27","author":"Sechter","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","article-title":"A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression","volume":"21","author":"Vanelle","year":"2006","journal-title":"European Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006624.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S0924-977X(04)80338-9","article-title":"Metabolic control in patients with comorbid schizophrenia and depression treated with amisulpride or olanzapine","volume":"14","author":"Vanelle","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006624.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.biopsych.2005.07.012","article-title":"Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine","volume":"59","author":"Quednow","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.npp.1300626","article-title":"Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride","volume":"30","author":"Wagner","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006624.pub2-BIB0017|cit17","first-page":"S403","article-title":"Side effects of atypical antipsychotics - prediction factor for compliance","volume":"16","author":"Baloescu","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0018|cit18","unstructured":"Beuzen JN Pans M Modell S Hagens P McQuade R Iwamoto T Carson W Naturalistic study of aripiprazole treatment Proceedings of the XIII World Congress of Psychiatry; 2005 Sept 10-15th; Cairo, Egypt 2005"},{"issue":"2-3","key":"10.1002\/14651858.CD006624.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0924-977X(99)80308-3","article-title":"Social adaptation in schizophrenic patients: experience with amisulpride","volume":"9","author":"Giudicelli","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006624.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0022|cit22","unstructured":"M\u00f6ller HJ Amisulpride A non conventional antipsychotic Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France 1997"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s004060200006","article-title":"Neurocognitive performance in first-episode and chronic schizophrenic patients","volume":"252","author":"Moritz","year":"2002","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-977X(01)80312-6","article-title":"Social functioning and quality of life in schizophrenia: experience with amisulpride","volume":"11","author":"Oli\u00e9","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0025|cit25","first-page":"100","article-title":"Neuroendocrine effects of typical and atypical antipsychotic agents in schizophrenic patients","volume":"17","author":"Oliveira-Castro","year":"1991","journal-title":"Encephale"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0026|cit26","first-page":"191","article-title":"Alterations of glucose metabolism under treatment with clozapine vs. amisulpride","volume":"67","author":"Rettenbacher","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006624.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0924-977X(06)70530-2","article-title":"Association of leptin gene polymorphism with antipsychotic drug-induced weight gain","volume":"16","author":"Ryu","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006624.pub2-BIB0028|cit28","first-page":"S135","article-title":"Depressive symptoms under atypical neuroleptic treatment in schizophrenia","volume":"71","author":"Yagdiran","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0029|cit29","unstructured":"Anon Risperdal consta clinical protocol RIS-SCH-4055 Clinical Trial Agreement For Pharmaceutical Industry Sponsored Research In NHS Trust 2005"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-993209","article-title":"Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial","volume":"41","author":"Assion","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0031|cit31","unstructured":"Beuzen J-N Pans M Modell S Hagens P McQuade R Iwamato T Broad effectiveness trial with aripiprazole in Europe Eu-Beta Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany 2005"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0032|cit32","unstructured":"Beuzen J-N Schirr K Pans M Hagens P Kostic D Carson W Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/00048670903487134","article-title":"Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial","volume":"44","author":"Bhowmick","year":"2010","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1017\/S0033291704224084","article-title":"Untitled","volume":"35","author":"Birchwood","year":"2005","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0035|cit35","unstructured":"Dazzan P Optimization of treatment and management of schizophrenia in europe study - double blind (amisulpride or olanzapine) - optimise2 http:\/\/public.ukcrn.org.uk\/ 2011"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0036|cit36","unstructured":"DRKS00003603 A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients.-combine http:\/\/apps.who.int\/ 2012"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0039|cit37","unstructured":"Boter H The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens http:\/\/www.controlled-trials.com 2005"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0037|cit38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4088\/JCP.08m04506yel","article-title":"Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)","volume":"71","author":"Boter","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006624.pub2-BIB0038|cit39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006624.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"\"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)\": correction","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006624.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006624.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euroneuro.2010.02.001","article-title":"Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)","volume":"20","author":"Gaebel","year":"2010","journal-title":"European Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006624.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2009.09.022","article-title":"Correlates of cognitive impairment in first episode schizophrenia: The eufest study","volume":"115","author":"Galderisi","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006624.pub2-BIB0046|cit44","first-page":"A24","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"2","author":"Kahn","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0044|cit45","first-page":"S56","article-title":"EUFEST: A randomized pragmatic long-term trial in first episode schizophrenia","volume":"20","author":"Kahn","year":"2005","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0045|cit46","unstructured":"Kahn R Fleischhacker WW Karayal O Siu C Pappadopulos E EUFEST: the effects of first and second generation antipsychotics on metabolic and cardiovascular risk factors Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0048|cit47","unstructured":"Kahn RS Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0049|cit48","unstructured":"Kahn RS Effectiveness of second-generation antipsychotics in first episode schizophrenia: the EUFEST study Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"issue":"9618","key":"10.1002\/14651858.CD006624.pub2-BIB0047|cit49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/JCP.0b013e3182199bcc","article-title":"Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial","volume":"31","author":"Malik","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0051|cit51","unstructured":"NTR25 The european first episode schizophrenia trial (eufest): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens http:\/\/www.trialregister.nl\/trialreg\/index.asp 2005"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0052|cit52","first-page":"82","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder","volume":"12","author":"No","year":"2009","journal-title":"African Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0924-977X(10)70687-8","article-title":"Polish patients of the eufest study after 1 year antipsychotic treatment: Drug discontinuation and metabolic syndrome parameters","volume":"1","author":"Rabe-Jablonska","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0054|cit54","unstructured":"Rybakowski JK Vansteelandt K Szafranski T Thys E Jarema M Wolfgang Fleischhacker W Treatment of depression in first episode of schizophrenia: Results from eufest European Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD006624.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.schres.2010.02.958","article-title":"Depressive symptoms in the first episode of schizophrenia - analysis of polish results of the eufest study","volume":"117","author":"Szafranski","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"7","key":"10.1002\/14651858.CD006624.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4088\/JCP.10m06529","article-title":"Efficacy of antipsychotic drugs against hostility in the european first-episode schizophrenia trial (eufest)","volume":"72","author":"Volavka","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0057|cit57","unstructured":"Fleischhacker WW Safety and tolerability of first and second generation antipsychotics Proceedings of the World Psychiatric Association International congress; 2009 April 1-4th; Florence Italy 2009"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02849987","article-title":"Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study","volume":"24","author":"Genc","year":"2007","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2007-1004592","article-title":"Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia","volume":"3","author":"Goder","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0060|cit60","unstructured":"Haro J Amisulpride and quetiapine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0061|cit61","unstructured":"ISRCTN68824876 Amisulpride augmentation in clozapine-unresponsive schizophrenia http:\/\/www.controlled-trials.com 2010"},{"issue":"2-3","key":"10.1002\/14651858.CD006624.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.schres.2010.02.681","article-title":"Large effect of baseline treatment with long acting antipsychotic drugs on randomized treatment outcomes","volume":"117","author":"Barnes","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD006624.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006624.pub2-BIB0064|cit64","first-page":"S244","article-title":"Effect of amisulpride and olanzapine on neuropsychological performance in schizophrenic patients: a sub-analysis of a double-blind, randomized clinical trial","volume":"7","author":"Joyce","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006624.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.pnpbp.2007.07.005","article-title":"Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial","volume":"31","author":"Kim","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006624.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S0924-977X(07)70666-1","article-title":"Effectiveness of switching from risperidone to amisulpride in stabilized schizophrenic patients with depression","volume":"17","author":"Kim","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006624.pub2-BIB0067|cit67","first-page":"S409","article-title":"A double-blind, randomized clinical trial of amisulpride and olanzapine in acute schizophrenia: patient responder profile","volume":"7","author":"Lecrubier","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006624.pub2-BIB0068|cit68","first-page":"S31","article-title":"First generation versus second generation (non-clozapine) antipsychotic drugs versus clozapine in schizophrenia: the Cutlass trials","volume":"30","author":"Lewis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Mahmoud A Hayhurst KP Drake RJ Lewis SW Second generation antipsychotics improve sexual dysfunction in schizophrenia: A randomised controlled trial http:\/\/www.hindawi.com\/journals\/sprt\/2011\/596898\/ 10.1155\/2011\/596898","DOI":"10.1155\/2011\/596898"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0071|cit70","unstructured":"Peuskens J Less weight gain with amisulpride: results from double-blind studies vs. risperidone and olanzapine Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic 2003"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0070|cit71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/YIC.0b013e3280148c29","article-title":"Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine","volume":"22","author":"Peuskens","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/ebmh.10.2.57","article-title":"Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia","volume":"10","author":"McCue","year":"2007","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0073|cit73","unstructured":"Moore N Switching to aripiprazole from other second-generation antipsychotics Australian New Zealand Clinical Trials Registry 2006"},{"issue":"7","key":"10.1002\/14651858.CD006624.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hup.865","article-title":"Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia","volume":"22","author":"Mortimer","year":"2007","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0075|cit75","unstructured":"NCT00419653 Modulation of regional brain activation in schizophrenic patients by pharmacological therapy with amisulpride, olanzapine or haloperidol a study with functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) http:\/\/www.clinicaltrials.gov 2007"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0076|cit76","unstructured":"NCT00761670 Efficacy study on cognitive functions in schizophrenic patients http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0077|cit77","unstructured":"NCT00926965 Tardive dyskinesia and cognitive function http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0078|cit78","unstructured":"NCT00956189 Identification and treatment response prediction of antipsychotic-related metabolic syndrome http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0079|cit79","unstructured":"NCT01029769 The switch study - efficacy of an early antipsychotic switch in case of poor initial response to the treatment of schizophrenia http:\/\/www.clinicaltrials.gov 2009"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0080|cit80","unstructured":"Barnes T Amisulpride augmentation in clozapine-unresponsive schizophrenia - AMICUS http:\/\/public.ukcrn.org.uk 2011"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0081|cit81","unstructured":"NCT01246232 Amisulpride augmentation in clozapine-unresponsive schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01246232 2010"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0082|cit82","unstructured":"NCT01446328 Bergen psychosis project 2 http:\/\/ClinicalTrials.gov\/show\/NCT01446328 2011"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0083|cit83","unstructured":"NCT01448499 Clozapine versus amisulpride in treatment-resistant schizophrenia patients http:\/\/ClinicalTrials.gov\/show\/NCT01448499 2011"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0084|cit84","unstructured":"NCT01609153 Is an antipsychotic combination treatment of olanzapine and amisulpride more effective than monotherapy http:\/\/ClinicalTrials.gov\/show\/NCT01609153 2012"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3111\/200306031041","article-title":"Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia","volume":"6","author":"Nicholls","year":"2002","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0086|cit86","unstructured":"Pfizer Down-titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open-label, three-months study http:\/\/www.clinicalstudyresults.org\/ 2006"},{"issue":"4","key":"10.1002\/14651858.CD006624.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0269881106069467","article-title":"Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study","volume":"21","author":"Rettenbacher","year":"2007","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eurpsy.2008.10.005","article-title":"A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients","volume":"24","author":"Riedel","year":"2009","journal-title":"European Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.psiq.2010.07.002","article-title":"Pharmacological augmentation strategies in clozapine-resistant schizophrenia: Overcoming the resistance","volume":"17","author":"Ruiz-Doblado","year":"2010","journal-title":"Psiquiatria Biologica"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/13651500510018266","article-title":"Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics","volume":"9","author":"Schimmelmann","year":"2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0091|cit91","first-page":"A99","article-title":"Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy","volume":"21","author":"Schmechtig","year":"2011","journal-title":"Society for Neuroscience Abstract Viewer and Itinerary Planner"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0092|cit92","unstructured":"Schmechtig A Lees J Dawson G Dourish C Craig K Deakin B Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Schmechtig A Lees J Dawson GR Dourish CT Craig KJ Deakin JFW Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy Pharmacopsychiatry 2011 306","DOI":"10.1055\/s-0031-1292540"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/sj.npp.1300174","article-title":"Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month, double-blind study: correction","volume":"28","author":"Sechter","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006624.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/npp.2011.238","article-title":"Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial","volume":"37","author":"Shim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0096|cit96","first-page":"321","article-title":"Optimization of treatment and management of schizophrenia in europe: The optimise trial","volume":"1","author":"Somers","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006624.pub2-BIB0097|cit97","first-page":"S243","article-title":"An 8-week double blind, randomized trial comparing amisulpride and olanzapine in schizophrenic patients with depression","volume":"7","author":"Vanelle","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0099|cit99","volume-title":"Scale for the assessment of negative symptoms","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0100|cit100","first-page":"1","volume-title":"Practice guidelines for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006624.pub2-BIB0103|cit103","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0106|cit106","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006624.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004850-199705002-00004","article-title":"Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies","volume":"12","author":"Freeman","year":"1997","journal-title":"International clinical psychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0114|cit114","volume-title":"Treatment guidelines for schizophrenia","author":"Gaebel","year":"2006"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1176\/ajp.149.9.1148","article-title":"Revising axis V for DSM-IV: a review of mesures of social functioning","volume":"149","author":"Goldman","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Guy U ECDEU assessment manual for psychopharmacology National Institute of Mental Health 1976","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0123|cit123","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0124|cit124","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \"atypical\" antipsychotic: A meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Liebermann","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001357","article-title":"Amisulpride for schizophrenia","author":"Mota Neto","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0133|cit133","first-page":"329","article-title":"New assessment of atypical antipsychotics","volume":"71","author":"M\u00f6ller","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199705002-00005","article-title":"Clinical update on amisulpride in deficit schizophrenia","volume":"12","author":"Rein","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0136|cit136","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006624.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0141|cit141","unstructured":"WHO Mental Health: New Understanding, New Hope The World Health report 2001"},{"key":"10.1002\/14651858.CD006624.pub2-BIB0142|cit142","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007 2007"},{"issue":"2","key":"10.1002\/14651858.CD006624.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A Meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006624.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:13:34Z","timestamp":1722665614000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006624.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":143,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006624.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}